Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease

Abstract excerpt

<title>Abstract</title> <p>Senescent cell accumulation contributes to the progression of age-related disorders including Alzheimer’s disease (AD). Clinical trials evaluating senolytics, drugs that clear senescent cells, are underway, but lack standardized outcome measures. Our team recently published data from the first open-label trial to evaluate senolytics (dasatinib plus quercetin) in AD. After 12-weeks of in...

Topics

Open a Topic to create a Post that cites this publication.

• Alzheimer's disease research and treatments
• Bioinformatics and Genomic Networks
• Circadian rhythm and melatonin
• Computational Drug Discovery Methods
• Dementia and Cognitive Impairment Research
• GDF15 and Related Biomarkers
• Neuroinflammation and Neurodegeneration Mechanisms
• Telomeres, Telomerase, and Senescence

Identifiers and source

Literature Corpus work

68992629-1d5d-595d-a15e-32fe625f27aa

DOI

10.21203/rs.3.rs-3994894/v1